LearnGlossaryMarketStocksSuperinvestorsSign in

ABCL

AbCellera Biologics Inc.

Healthcare · $3.4B market cap

Verdict

We can't put a fair value on ABCL right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth7.7% a year✗
Equity per share growth-8.4% a year✗
Sales growth32.7% a year✓
Free cash flow growth10.0% a year✗
Return on invested capital-16.0%✗

Follow ABCL

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

None of the investors we track holds ABCL right now. In Q1 2026, 1 sold out. Who we track

Moves in Q1 2026

Sold out: Polen Capital Management

About AbCellera Biologics Inc.

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works